Market Closed -
Nasdaq
16:00:00 2024-04-29 EDT
|
5-day change
|
1st Jan Change
|
4.14
USD
|
+9.23%
|
|
+10.99%
|
+96.21%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
271.7
|
493.7
|
392.8
|
922.6
|
1,146
|
2,438
|
-
|
-
|
Enterprise Value (EV)
1 |
271.7
|
493.7
|
392.8
|
922.6
|
1,162
|
2,296
|
2,317
|
2,103
|
P/E ratio
|
-3.78
x
|
-5.68
x
|
-3.49
x
|
-6.54
x
|
-6.59
x
|
-12.2
x
|
-24.8
x
|
71.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
591
x
|
1,951
x
|
282
x
|
1,548
x
|
4,835
x
|
44.3
x
|
10.5
x
|
5.32
x
|
EV / Revenue
|
591
x
|
1,951
x
|
282
x
|
1,548
x
|
4,902
x
|
41.7
x
|
10
x
|
4.59
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-6
x
|
-10.7
x
|
-43.4
x
|
13.4
x
|
EV / FCF
|
-6.14
x
|
-2.87
x
|
-3.38
x
|
-
|
-
|
-12.2
x
|
-27.6
x
|
23.4
x
|
FCF Yield
|
-16.3%
|
-34.8%
|
-29.6%
|
-
|
-
|
-8.19%
|
-3.63%
|
4.28%
|
Price to Book
|
2.01
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
199,778
|
310,472
|
321,949
|
381,235
|
543,064
|
588,874
|
-
|
-
|
Reference price
2 |
1.360
|
1.590
|
1.220
|
2.420
|
2.110
|
4.140
|
4.140
|
4.140
|
Announcement Date
|
20-03-12
|
21-03-11
|
22-03-10
|
23-03-16
|
24-02-28
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.46
|
0.253
|
1.393
|
0.596
|
0.237
|
55.06
|
231.8
|
458.2
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-193.5
|
-214.3
|
-53.35
|
156.4
|
EBIT
1 |
-72.5
|
-76.91
|
-114
|
-138.6
|
-193.9
|
-214.6
|
-101.7
|
66.55
|
Operating Margin
|
-15,761.96%
|
-30,400.4%
|
-8,183.7%
|
-23,246.64%
|
-81,832.91%
|
-389.72%
|
-43.87%
|
14.53%
|
Earnings before Tax (EBT)
1 |
-68.55
|
-75.62
|
-116.1
|
-141.9
|
-184.1
|
-210.3
|
-97.09
|
51
|
Net income
1 |
-68.55
|
-75.62
|
-116.1
|
-141.9
|
-184.1
|
-211.2
|
-108.7
|
48.24
|
Net margin
|
-14,901.74%
|
-29,888.14%
|
-8,335.39%
|
-23,808.89%
|
-77,690.72%
|
-383.48%
|
-46.92%
|
10.53%
|
EPS
2 |
-0.3600
|
-0.2800
|
-0.3500
|
-0.3700
|
-0.3200
|
-0.3383
|
-0.1667
|
0.0580
|
Free Cash Flow
1 |
-44.24
|
-172
|
-116.1
|
-
|
-
|
-188
|
-84
|
90
|
FCF margin
|
-9,617.83%
|
-67,973.12%
|
-8,334.82%
|
-
|
-
|
-341.43%
|
-36.24%
|
19.64%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
57.55%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
186.56%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-12
|
21-03-11
|
22-03-10
|
23-03-16
|
24-02-28
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.109
|
1.04
|
0.123
|
0.073
|
0.297
|
0.103
|
0.021
|
0.029
|
0.164
|
0.023
|
0.0288
|
0.0288
|
19.2
|
35.82
|
52.03
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-25.67
|
-30.98
|
-28.68
|
-27.98
|
-39.95
|
-41.95
|
-40.09
|
-51.95
|
-47.61
|
-54.29
|
-58.43
|
-64.61
|
-50.77
|
-40.78
|
-34.33
|
Operating Margin
|
-23,554.13%
|
-2,979.04%
|
-23,313.01%
|
-38,323.29%
|
-13,450.51%
|
-40,729.13%
|
-190,914.29%
|
-179,141.38%
|
-29,031.71%
|
-236,039.13%
|
-202,660.91%
|
-224,090.5%
|
-264.45%
|
-113.86%
|
-65.98%
|
Earnings before Tax (EBT)
1 |
-26.7
|
-32.02
|
-30.1
|
-28.12
|
-41.05
|
-42.64
|
-38.12
|
-49.23
|
-44.8
|
-51.97
|
-56.68
|
-63.46
|
-49.56
|
-40.57
|
-24.9
|
Net income
1 |
-26.7
|
-32.02
|
-30.1
|
-28.12
|
-41.05
|
-42.64
|
-38.12
|
-49.23
|
-44.8
|
-51.97
|
-56.82
|
-63.47
|
-49.74
|
-41.12
|
-33.33
|
Net margin
|
-24,492.66%
|
-3,078.56%
|
-24,469.92%
|
-38,516.44%
|
-13,821.89%
|
-41,393.2%
|
-181,533.33%
|
-169,748.28%
|
-27,320.12%
|
-225,973.91%
|
-197,079.43%
|
-220,135.87%
|
-259.07%
|
-114.81%
|
-64.06%
|
EPS
2 |
-0.0800
|
-0.1000
|
-0.0900
|
-0.0700
|
-0.1000
|
-0.1000
|
-0.0700
|
-0.0900
|
-0.0800
|
-0.0900
|
-0.0967
|
-0.1050
|
-0.0783
|
-0.0600
|
-0.0500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-09
|
22-03-10
|
22-05-09
|
22-08-11
|
22-11-03
|
23-03-16
|
23-05-11
|
23-08-03
|
23-11-02
|
24-02-28
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
15.9
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
142
|
121
|
335
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.082
x
|
-
|
-
|
-
|
Free Cash Flow
1 |
-44.2
|
-172
|
-116
|
-
|
-
|
-188
|
-84
|
90
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
0.6800
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.41
|
0.4
|
0.21
|
-
|
-
|
5
|
7
|
9
|
Capex / Sales
|
89.78%
|
158.5%
|
14.86%
|
-
|
-
|
9.08%
|
3.02%
|
1.96%
|
Announcement Date
|
20-03-12
|
21-03-11
|
22-03-10
|
23-03-16
|
24-02-28
|
-
|
-
|
-
|
Last Close Price
4.14
USD Average target price
5.786
USD Spread / Average Target +39.75% Consensus |
1st Jan change
|
Capi.
|
---|
| +96.21% | 2.44B | | -2.63% | 102B | | +1.62% | 96.29B | | +1.46% | 22.18B | | -16.67% | 21.2B | | -8.58% | 18.31B | | -38.74% | 17.38B | | -13.21% | 16.36B | | +5.41% | 13.97B | | +33.57% | 12.17B |
Bio Therapeutic Drugs
|